Journal of Clinical and Translational Hepatology

Papers
(The H4-Index of Journal of Clinical and Translational Hepatology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options47
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver47
NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States35
Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review32
Incidence, Mortality and Predictors of Acute Kidney Injury in Patients with Cirrhosis: A Systematic Review and Meta-analysis32
Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases30
Macrophage Phenotypes and Hepatitis B Virus Infection29
Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease29
What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective27
Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study26
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD25
Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak21
Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?20
Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications20
Liver Dysfunction and Its Association with the Risk of Death in COVID-19 Patients: A Prospective Cohort Study19
Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy18
Antihepatic Fibrosis Drugs in Clinical Trials18
Ginsenoside Rb1 Reduces D-GalN/LPS-induced Acute Liver Injury by Regulating TLR4/NF-κB Signaling and NLRP3 Inflammasome18
0.037436008453369